Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 High Potency Product Manufacturing | Contract Pharma
White Papers / Tech Papers

High Potency Product Manufacturing

 

 High Potency Product Manufacturing 

Key selection criteria when evaluating an outsourcing partner
Summary 

Approximately 25% of drugs in development worldwide are classified as highly potent, with this percentage expected to grow over the coming years. A compound is generally classed as highly potent if it has an occupational exposure limit (OEL) of ≤10μg/m3, a daily therapeutic dose of ≤10mg/day or if a 1 mg/kg/day dose produces serious toxicity in laboratory animals. While such highly potent compounds can have significant benefits in the treatment of certain medical conditions, they present substantial challenges to the pharmaceutical industry. 

These challenges include: can personnel and the environment involved in the manufacture of high potency products be protected; can adequacy of controls preventing contamination of other products by high potent materials be demonstrated; and can expectations of clients and/or regulators regarding separation or segregation of manufacturing activities be satisfied?

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters